<DOC>
	<DOCNO>NCT01463631</DOCNO>
	<brief_summary>This study evaluate safety tolerability different dos experimental treatment participant advance cancer .</brief_summary>
	<brief_title>A Study LY3007113 Participants With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer advance and/or metastatic available standard therapy fail provide clinical benefit disease For Dose Escalation ( Part A ) : cancer , either solid tumor lymphoma For Dose Confirmation ( Part B ) : cancer , either solid tumor lymphoma Have presence measureable nonmeasureable disease ( Part A ) measureable disease ( Part B ) define Response Evaluation Criteria Solid Tumors Revised Response Criteria Malignant Lymphoma Have adequate hematologic , hepatic renal function Have performance status less equal 2 Eastern Cooperative Oncology Group scale Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent Have estimate life expectancy great equal 12 week Are able swallow capsule Have echocardiogram clinically significant abnormality For Dose Escalation ( Part A ) : Have central nervous system malignancy metastasis For Dose Confirmation ( Part B ) : Have symptomatic central nervous system malignancy metastasis Have acute leukemia Have history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission stop therapy disease minimum 3 year Have receive autologous allogeneic stemcell transplant within 75 day initial dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>